Major efficacy and safety outcomes at day 42 in the CACTUS trial
| . | Therapeutic nadroparin (n = 122), No. (%) . | Placebo (n = 130), No. (%) . | Absolute risk difference, % (95% CI) . | P . |
|---|---|---|---|---|
| Primary outcome by day 42 | 4 (3.3) | 7 (5.4) | −2.1 (−7.8 to 3.5) | .54 |
| Proximal DVT | 2 (1.6) | 7 (5.4) | — | — |
| PE | 2 (1.6) | 0 (0.0) | — | — |
| Major bleeding or nonmajor clinically relevant bleeding | 5 (4.1) | 0 (0.0) | 4.1 (0.4 to 9.2) | .03 |
| Major bleeding | 1 (0.8) | 0 (0.0) | — | — |
| Nonmajor clinically relevant bleeding | 4 (3.3) | 0 (0.0) | — | — |
| . | Therapeutic nadroparin (n = 122), No. (%) . | Placebo (n = 130), No. (%) . | Absolute risk difference, % (95% CI) . | P . |
|---|---|---|---|---|
| Primary outcome by day 42 | 4 (3.3) | 7 (5.4) | −2.1 (−7.8 to 3.5) | .54 |
| Proximal DVT | 2 (1.6) | 7 (5.4) | — | — |
| PE | 2 (1.6) | 0 (0.0) | — | — |
| Major bleeding or nonmajor clinically relevant bleeding | 5 (4.1) | 0 (0.0) | 4.1 (0.4 to 9.2) | .03 |
| Major bleeding | 1 (0.8) | 0 (0.0) | — | — |
| Nonmajor clinically relevant bleeding | 4 (3.3) | 0 (0.0) | — | — |